TEGRETOL-XR Drug Patent Profile

When do Tegretol-xr patents expire, and when can generic versions of Tegretol-xr launch?

Tegretol-xr is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in TEGRETOL-XR is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tegretol-xr

A generic version of TEGRETOL-XR was approved as carbamazepine by TARO on October 3^rd, 1996.

Summary for TEGRETOL-XR

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for TEGRETOL-XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEGRETOL-XR	Extended-release Tablets	carbamazepine	100 mg	020234	1	2005-12-30

US Patents and Regulatory Information for TEGRETOL-XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-001	Mar 25, 1996	AB	RX	Yes	No
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-002	Mar 25, 1996	AB	RX	Yes	No
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-003	Mar 25, 1996	AB	RX	Yes	Yes

International Patents for TEGRETOL-XR

See the table below for patents covering TEGRETOL-XR around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	873409
United Kingdom	8717643
Denmark	175497
Japan	2592460
Australia	7661787

Investment Scenario and Fundamentals Analysis for TEGRETOL XR

Last updated: February 20, 2026

What are the core market dynamics for TEGRETOL XR?

TEGRETOL XR (carbamazepine extended-release) is an antiepileptic drug, primarily used in the control of seizure disorders, trigeminal neuralgia, and bipolar disorder. Market valuation hinges on its established therapeutic efficacy, patent status, regulatory approvals, and competitive landscape.

The global epilepsy market was valued at approximately USD 7.07 billion in 2022, growing at a compound annual growth rate (CAGR) of 4-6%, projected to reach USD 10 billion by 2028. TEGRETOL XR holds a significant share, driven by its early entry, well-established efficacy, and physician familiarity.

The key drivers include an increasing prevalence of epilepsy—estimated at 50 million worldwide—as well as rising rates of neuropsychiatric disorders. However, generic competition, especially following patent expirations, diminishes profitability outlooks for brand-name drugs like TEGRETOL XR.

---

What are the patent and regulatory considerations?

TEGRETOL XR's patent protection has been crucial. Its original patent expired in the U.S. in 2014, after which generic versions entered the market. The drug's extended-release formulation received FDA approval in 1999, with exclusivity periods largely expired by the early 2010s.

In recent years, patent litigation or exclusivity extensions can influence the timing of generic entry. As of 2023, the U.S. market sees multiple generics, reducing TEGRETOL XR's market share and potentially impacting revenue streams.

European markets have similar patent expirations, with regulatory approvals largely aligned with the U.S. timeline. No major regulatory hurdles appear to threaten continued approval, but competition remains strong.

---

How does the competitive landscape impact investment prospects?

The primary competition includes both original formulators and generic manufacturers:

Competitor	Market Share	Key Differentiator	Approval Status
Generic manufacturers	80-90% (U.S. market)	Lower price	Approved widely
Tegretol XR	Remaining share	Brand recognition, established efficacy	Marketed with reduced exclusivity

The transition from brand to generic markets usually results in revenue declines. TEGRETOL XR sales have decreased by approximately 30-40% post-generic entry, with stable revenues often sustained through worldwide markets with residual brand loyalty.

Major players include Novartis (original marketer), with other pharmaceutical companies such as Teva, Mylan, and Sandoz actively marketing generics.

---

What financial trends influence investment decisions?

Data from company filings and industry reports show:

• Sales decline: TEGRETOL XR revenues have decreased from USD 600 million in 2014 to USD 350 million in 2022.
• Profit margins: Raw margin erosion due to generic competition, with branded versions offsetting some losses through marketing efforts and formulations.
• Research & Development (R&D): Limited pipeline suggests reduced focus on TEGRETOL XR-specific innovation.

Investors should note that profit margins for generic drugs often range between 10-15%, while branded formulations typically have margins of 40-50%. The decline in sales volume correlates with increasing generic market penetration.

---

What is the outlook for future growth or decline?

Factors favoring continued investment include:

• Long-term patents or exclusivity extensions: Unlikely for TEGRETOL XR given expiration history.
• New indications or formulations: No recent approvals suggest minimal pipeline activity.
• Emerging markets: Growing healthcare infrastructure in Asia-Pacific and Latin America could impact sales positively, but price-based competition remains fierce.

Potential decline remains the dominant trend, with an annualized decrease in sales of 5-8%, barring significant regulatory or formulary shifts.

---

What are the key risks and opportunities?

Risks	Opportunities
Intensified generic penetration	Developing novel formulations or delivery systems
Regulatory changes reducing reimbursement	Expanding to emerging markets with less competition
Price erosion from formularies	Licensing or partnership deals to expand therapeutic uses

Suspension, contraindications, or adverse effects also pose risks, but no recent data suggest significant safety issues affecting TEGRETOL XR’s market.

---

Key Takeaways

• TEGRETOL XR's market is mature, with revenues declining due to patent expirations and generic competition.
• The drug maintains a solid therapeutic profile but faces revenue erosion.
• Investment prospects depend heavily on geographic diversification and potential new indications.
• Limited pipeline and patent protection reduce upside potential.
• Long-term risks include further price erosion and regulatory pressures.

---

Frequently Asked Questions

1. What is the current patent status of TEGRETOL XR?
The original patent expired in 2014 in the U.S., with subsequent patent protections or exclusivity periods varying by jurisdiction. International patent statuses are similar, leading to widespread generic availability.

2. How does generic competition impact TEGRETOL XR’s sales?
Generic entry reduces revenues significantly post-patent expiry; American sales have declined 30-40% since generics entered the market.

3. Are there pending regulatory or legal barriers?
No recent regulatory or legal hurdles threaten continued approval; however, patent lawsuits and exclusivity challenges remain historical factors.

4. Is there potential for new indications or formulations?
No recent approvals or development efforts focus on expanding TEGRETOL XR’s approved indications; pipeline activity appears limited.

5. How viable are emerging markets for the drug?
Emerging markets offer growth potential through increased healthcare coverage, but price sensitivity and local competition impact profitability.

---

References

[1] IQVIA. (2023). Global Epilepsy Market Report.
[2] FDA. (2023). Drug Approval and Patent Data for Carbamazepine.
[3] MarketWatch. (2022). Pharmaceutical Sales and Market Share Analytics.
[4] FDA. (2019). Formulary and Patent Exclusivity Information.
[5] WHO. (2022). Global Prevalence of Epilepsy.